Loading clinical trials...
Loading clinical trials...
Phase 1 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions
Interventions
Ibrutinib
Locations
8
Japan
Fukuoka, Japan
Hiroshima, Japan
Isehara, Japan
Kobe, Japan
Kōtoku, Japan
Osaka, Japan
Start Date
July 3, 2015
Primary Completion Date
August 20, 2018
Completion Date
August 20, 2018
Last Updated
August 14, 2019
NCT05006716
NCT07277231
NCT06859424
NCT06481735
NCT01804686
NCT05442515
Lead Sponsor
Janssen Pharmaceutical K.K.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions